The in vitro antifungal activity of micafungin (MCFG) against Candida and Aspergillus species, clinically isolated in Japan between October 2001 and August 2002, were compared with those of amphotericin-B, miconazole, fluconazole, itraconazole and 5-fluorocytosine using the broth microdilution method, as specified by the National Committee for Clinical Laboratory Standards (NCCLS) documents M
... [Show full abstract] 27-A and M 38-P. The MIC90 levels of MCFG for Candida albicans (including fluconazole-resistant isolates), Candida tropicalis, Candida glabrata, and other Candida spp. were 0.0625 μg/mL or lower, which were lower than those for the other antifungal agents tested. The MICs of MCFG for Candida parapsilosis and Candida guilliermondii ranged from 0.025 to 1 μg/mL, which were comparable to or slightly higher than those for the other antifungal agents tested. The MICs of MCFG for Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, Aspergillus flavus and other Aspergillus sp. ranged from 0.002 to 0.0313 μg/mL, which were lower than those for the other antifungal agents tested. None of the isolates showed a lowered susceptibility to MCFG, as indicated by the fact that the MIC values of MCFG were distributed within 2 dilutions for each Candida species and below 0.0313 μg/mL for all Aspergillus isolates.